SUNCAP, a phase II study with sunitinib and capecitabine in patients with metastatic colorectal cancer (MCRC) refractory to previous treatment with 5FU/irinotecan/oxaliplatin.

被引：6
|
作者：
Samson, B.
Latreille, J.
Nguyen, N. T.
Sperlich, C.
Berbiche, D.
Tournigand, C.
机构：
[1] CICM, Hop Charles LeMoyne, Greenfield Pk, PQ, Canada
[2] Hop Charles LeMoyne, Ctr Rech, Longueuil, PQ, Canada
[3] Hop St Antoine, F-75571 Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
545
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Phase II study of oxaliplatin (OHP) and protracted 5-fluorouracil (5FU) infusion in pretreated metastatic colorectal cancer (MCRC) patients
    Mini, E
    Pinto, C
    Angelelli, B
    Dentico, P
    Piana, E
    Nobili, S
    Gentile, AL
    Scicolone, S
    Mazzei, T
    Martoni, A
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 73 - 73
  • [3] A phase II study of capecitabine, oxaliplatin and irinotecan (XELOXIRI) as salvage therapy in patients with refractory metastatic colorectal cancer.
    Kwok, Gin Wai
    Leung, Roland Ching-Yu
    Chiu, Joanne
    Tang, Vikki
    Yau, Thomas Cheung
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] First-line treatment of metastatic colorectal cancer (MCRC) with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the GONO group
    Masi, G.
    Loupakis, F.
    Baldi, G.
    Fornaro, L.
    Stasi, I
    Vasile, E.
    Cialo, A.
    Cavaciocchi, D.
    Di Leo, A.
    Puglisi, M.
    Ciprotti, M.
    Amoroso, D.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [5] FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the GONO group
    Falcone, A.
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Amoroso, D.
    Puglisi, M.
    Fea, E.
    Brunetti, I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] PHASE II STUDY OF FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) WITH GONO-FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) PLUS BEVACIZUMAB (BV)
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Ciprotti, M.
    Donati, S.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 136 - 137
  • [7] Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II GONO trial
    Masi, G.
    Salvatore, L.
    Fornaro, L.
    Vasile, E.
    Baldi, G. G.
    Stasi, I.
    Ciarlo, A.
    Tuzi, A.
    Andreuccetti, M.
    Falcone, A.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 346 - 346
  • [8] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) IN METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS OF A PHASE II GONO TRIAL
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cupini, Samanta
    Di Marsico, Roberta
    Antonuzzo, Andrea
    Baldi, Giacomo Giulio
    Stasi, Irene
    Pfanner, Elisabetta
    Ciarlo, Andrea
    Del Monte, Francesca
    Conte, Davide
    Iacovelli, Roberto
    Sonaglio, Claudia
    Granetto, Cristina
    Donati, Sara
    Andreuccetti, Michele
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [9] Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC).
    Meyerhardt, JA
    Xhu, A
    Enzinger, PC
    Ryan, DP
    Clark, JW
    Kulke, MH
    Michelini, A
    Vincitore, M
    Thomas, A
    Fuchs, CS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 265S - 265S
  • [10] Gemcitabine and capecitabine as third-line treatment in patients with metastatic colorectal cancer after failure of irinotecan and oxaliplatin.
    Qiu, M.
    Bi, F.
    Liu, J.
    Li, Q.
    Yi, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345